Selected tags: National Nanotechnology Initiative (NNI)

Regulating nanomaterials to life, not death

Richard Denison, Ph.D., is a Senior Scientist.

As we enter a new year and legislative season, we face a changed political climate where the thought of new regulation is anything but de rigueur.  I will argue in this post that a little regulation would have done – and still could do – the world of nanotechnology a world of good.

Come again?

Back when the debate over nanomaterial safety really got started, which I would place ‘round about 2004 (or was that just my first involvement in it?), there seemed to be broad agreement on first-order needs to ensure that nanotechnology would survive and thrive.  The aim was to “get it right the first time,” by identifying and addressing potential risks up front and in the open.  That meant we needed to adequately fund and direct risk research.  We also needed to make sure adequate regulatory authority existed to address potential risks, ideally before they arose.

Most fundamentally, there was virtual consensus on the need for prompt action to ensure regulatory agencies had at hand the basic information they needed to understand the lay of the nano-land:  what nanomaterials are already being produced and are in the pipeline; in what applications and products are they being used; and where along the nanomaterial lifecycle are the most likely points for potential releases and exposures.

With respect to this most fundamental of needs, I’m sorry to say that, in 2011, we are essentially no closer to achieving it than we were in 2004.  Read More »

Posted in Health Policy, Nanotechnology, Regulation| Also tagged , , , , | 3 Responses, comments now closed

Is the Window Closing?

Richard Denison, Ph.D., is a Senior Scientist.

As one who has closely followed the emergence of nanotechnology, I am sure I was not alone several years ago in welcoming what appeared to be a refreshingly new attitude among a broad range of stakeholders toward the introduction of this new set of technologies and materials.  Calls from my organization to "get nanotech right the first time" were echoed widely.  Perhaps the most frequently used metaphor, though, was that a "window of opportunity" had opened to do things differently this time.  But I increasingly fear that the window is closing. Read More »

Posted in Nanotechnology| Also tagged | 3 Responses, comments now closed

Clump Change: Challenging conventional wisdom about nanoparticle aggregation

Richard Denison, Ph.D., is a Senior Scientist.

In some nanotechnology circles, it is almost a mantra that, once released to the environment, nanoparticles will inevitably aggregate or agglomerate into larger masses and thereby lose their nanoscale-related properties and, by implication at least, any associated risks.

But can we count on nanoparticles released to the environment to self-regulate their own risk so conveniently? Read More »

Posted in Nanotechnology| Also tagged , | Comments closed

Mid-course Corrections: House Passes NNI Reauthorization Bill

Richard Denison, Ph.D., is a Senior Scientist.

Yesterday the U.S. House of Representatives overwhelmingly passed the National Nanotechnology Initiative Amendments Act of 2008 (H.R. 5940), by a vote of 407-6.  Among other changes, the bill calls for a number of much-needed improvements in how the NNI addresses health and environmental concerns associated with nanotechnology.  See EDF’s news release issued today.

Posted in Health Policy| Tagged | Comments closed

What Was the White House Thinking?

Richard Denison, Ph.D., is a Senior Scientist.

It’s been a few months now since the White House took the unusual step of articulating some “Principles for Nanotechnology EH&S Oversight.” Given recent events, it’s worth again reflecting on this official memorandum, which was signed by the heads of the White House’s Council on Environmental Quality (CEQ) and Office of Science and Technology Policy (OSTP) and sent to the heads of all federal agencies and departments.

Despite the title, it’s very hard not to read this document as one intended primarily to throw up barriers to effective oversight. Read More »

Posted in Health Policy, Nanotechnology, Regulation| Also tagged | 3 Responses, comments now closed

NNI's new strategy: Not quite

Richard Denison, Ph.D., is a Senior Scientist.

Just when you thought it might never emerge, the National Nanotechnology Initiative’s (NNI) Strategy for Nanotechnology-Related Environmental, Health and Safety Research [2.2 MB PDF] finally hit the streets last week.

It’s got good, bad and ugly. The good news is that here, at last, is a report from NNI that actually reads more like a strategy and less like yet another laundry list of research needs. The bad news is that key elements of a full strategy are still nowhere to be found. Read More »

Posted in Health Policy, Nanotechnology| Also tagged , | 1 Response, comments now closed
  • About this blog

    Science, health, and business experts at Environmental Defense Fund comment on chemical and nanotechnology issues of the day.

    Our work: Chemicals

  • Categories

  • Get blog posts by email

    Subscribe via RSS

  • Filter posts by tags

    • aggregate exposure (9)
    • Alternatives assessment (3)
    • American Chemistry Council (ACC) (55)
    • arsenic (3)
    • asthma (3)
    • Australia (1)
    • biomonitoring (9)
    • bipartisan (6)
    • bisphenol A (18)
    • BP Oil Disaster (18)
    • California (1)
    • Canada (7)
    • carbon nanotubes (24)
    • carcinogen (21)
    • Carcinogenic Mutagenic or Toxic for Reproduction (CMR) (12)
    • CDC (6)
    • Chemical Assessment and Management Program (ChAMP) (13)
    • chemical identity (30)
    • chemical testing (1)
    • Chemicals in Commerce Act (3)
    • Chicago Tribune (6)
    • children's safety (22)
    • China (10)
    • computational toxicology (10)
    • Confidential Business Information (CBI) (52)
    • conflict of interest (4)
    • consumer products (48)
    • Consumer Specialty Products Association (CSPA) (4)
    • contamination (4)
    • cumulative exposure (4)
    • data requirements (45)
    • diabetes (4)
    • DNA methylation (4)
    • DuPont (11)
    • endocrine disruption (28)
    • epigenetics (4)
    • exposure and hazard (49)
    • FDA (8)
    • flame retardants (20)
    • formaldehyde (15)
    • front group (13)
    • general interest (21)
    • Globally Harmonized System (GHS) (5)
    • Government Accountability Office (5)
    • hazard (6)
    • High Production Volume (HPV) (22)
    • in vitro (14)
    • in vivo (11)
    • industry tactics (41)
    • informed substitution (1)
    • inhalation (18)
    • IUR/CDR (27)
    • Japan (3)
    • lead (6)
    • markets (1)
    • mercury (4)
    • methylmercury (2)
    • microbiome (3)
    • nanosilver (6)
    • National Academy of Sciences (NAS) (20)
    • National Institute for Occupational Safety and Health (NIOSH) (7)
    • National Institute of Environmental Health Sciences (NIEHS) (5)
    • National Nanotechnology Initiative (NNI) (6)
    • obesity (6)
    • Occupational Safety and Health Administration (OSHA) (3)
    • Office of Information and Regulatory Affairs (OIRA) (4)
    • Office of Management and Budget (OMB) (15)
    • Office of Pollution Prevention and Toxics (OPPT) (3)
    • oil dispersant (18)
    • PBDEs (16)
    • Persistent Bioaccumulative and Toxic (PBT) (22)
    • pesticides (7)
    • phthalates (16)
    • polycyclic aromatic hydrocarbons (PAH) (5)
    • prenatal (6)
    • prioritization (35)
    • risk assessment (69)
    • Safe Chemicals Act (24)
    • Safer Chemicals Healthy Families (33)
    • Significant New Use Rule (SNUR) (19)
    • Small business (1)
    • South Korea (4)
    • styrene (6)
    • Substances of Very High Concern (SVHC) (15)
    • systematic review (1)
    • test rule (16)
    • tributyltin (3)
    • trichloroethylene (TCE) (3)
    • Turkey (3)
    • U.S. states (14)
    • vulnerable populations (1)
    • Walmart (2)
    • worker safety (23)
    • WV chemical spill (11)
  • Archives